The Study Collect Clinical Data From the Treatment of Liver Cancer With New Drugs After 2019 and Integrate Biochemical and Pathological Indicators to Analyze Prognostic Outcomes, Including Overall Survival, Progression-free Survival, and Complications.

The Theraprutic Effect of New Drugs for Hepatocellular Carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07233759

Enrollment

2500

Registered

2025-11-18

Start date

2023-01-31

Completion date

2026-12-31

Last updated

2025-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atezolizumab, Lenvatinib, Liver Cancer, Pembrolizumab

Brief summary

Hepatocellular carcinoma (HCC) is one of the most significant cancers in our country. Since 2019, many first-line and second-line therapeutic agents for HCC have been introduced. This study aims to evaluate the treatment outcomes of HCC patients in our hospital from 2019 to 2024 who received therapies other than the traditional sorafenib (Nexavar). The included drugs are Pembrolizumab, Atezolizumab (Tecentriq), Nivolumab, Lenvatinib, and Regorafenib (Stivarga). The study will collect clinical data from treated-cases with these novel agents after 2019 and integrate biochemical and pathological indicators to analyze prognostic outcomes, including overall survival, progression-free survival, and complications.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Inclusion criteria

* Hepatocellular carcinoma participants who received treatment at National Taiwan University Hospital between January 1, 2019, and June 30, 2026, and had used the following medications. 1. Pembrolizumab /keytruda 2. Atezolizumab / Tecentriq 3. Nivolumab 4. Lenvatinib 5. Stivarga

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame
liver cancer response of evaluation according to RECIST and mRECIST criteria	3 years

Countries

Taiwan

Outcome results